CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmusanT, Inc., a clinical-stage company developing Nexvax2®, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet in HLA-DQ2.5+ patients with celiac disease, today announced that Leslie Williams, Chief Executive Officer, will present on the company’s behalf and speak on a panel at the 2017 BIO Investor Forum, occurring October 17-18, 2017 in San Francisco, CA.
The panel, “Lessons from the Immuno-Oncology Inhibitor Landscape for Neurology and Beyond,” will explore how lessons learned from immuno-oncology can apply to diseases outside of oncology. Ms. Williams will address the parallels and differences in educating the immune system to treat autoimmune disease. The panel will include representatives from AbbVie, Atara Therapeutics and Merck & Co, Inc., and will take place 3:00-3:55pm PT on Wednesday, October 18.
ImmusanT’s company presentation, in which they will provide an update on the company’s clinical and business objectives, will take place at 3:00 PT on Tuesday, October 17.
About ImmusanT, Inc.
ImmusanT is a privately held
biotechnology company focused on protecting patients with celiac disease
against the effects of gluten. By harnessing new discoveries in
immunology, ImmusanT aims to improve diagnosis and medical management of
celiac disease by protecting against the effects of gluten exposure
while patients maintain a gluten-free diet. The company is developing Nexvax2®,
a therapeutic vaccine for celiac disease, and diagnostic and monitoring
tools to improve celiac disease management. ImmusanT’s targeted
immunotherapy discovery platform can be applied to a variety of
autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera
Healthcare Partners. More information may be found at www.ImmusanT.com,
or follow ImmusanT
on Twitter.
